Analysis of neointimal coverage after silolimus-eluting stent implantation using optical coherence tomography.

Similar documents
CLINICAL APPLICATIONS OF OPTICAL COHERENCE TOMOGRAPHY. Konstantina P. Bouki, FESC 2 nd Department of Cardiology General Hospital Of Nikea, Pireaus

Analysis of macrophage accumulation using optical coherence tomography one year after sirolimus, paclitaxel and zotarolimus-eluting stent

Clinical Application of OCT in Stent Evaluation

DESolve NX Trial Clinical and Imaging Results

Very late thrombosis of sirolimus-eluting stent due to late malapposition: Serial observations with optical coherence tomography

malapposition assessed by OCT

Neointimal coverage of bare-metal and sirolimuseluting stents evaluated with optical coherence tomography

Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome

Cover Page. Author: Wang, Ancong Title: Automatic quantification of intravascular optical coherence tomography Issue Date:

Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial

OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?

JACC: CARDIOVASCULAR INTERVENTIONS VOL. 2, NO. 5, PUBLISHED BY ELSEVIER INC. DOI: /j.jcin

Optical Coherence Tomography for Intracoronary Imaging

Post PCI functional testing and imaging: case based lessons from FFR React

Drug eluting stents (DES) have decreased

Catch-up Phenomenon: Insights from Pathology

Usefulness of OCT during coronary intervention

Evolution In Interventional Cardiology. Jawed Polad Jeroen Bosch Hospital s-hertogenbosch The Netherlands

1st Department of Cardiology, University of Athens, Hippokration Hospital, Athens, Greece

Acta Cardiol Sin 2018;34: doi: /ACS _34(2) A

Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators

INSIDE INFORMATION YOU CAN T IGNORE

Evaluation of stent placement and outcomes with optical coherence tomography

2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center

Drug Filled Stent Optical Coherence Tomography Results from RevElution Trial Stent Strut Coverage and Stent Apposition

Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents

OCT; Comparative Imaging Results with IVUS, VH and Angioscopy

Carotid Intravascular Imaging Technique and Indication

Appearance of Lipid-Laden Intima and Neovascularization After Implantation of Bare-Metal Stents

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

Biodegradable Stents An update and work-in

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT

For Personal Use. Copyright HMP 2014

HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?

FOR IMMEDIATE RELEASE

Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες

Clinical Value of OCT. Guidance for Coronary Stenting. Giulio Guagliumi, MD

MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION

INTRODUCTION. Catheterization and Cardiovascular Interventions 82:E871 E878 (2013)

Pathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL

Bioresorbable polymer drug-eluting stents in PCI

OCT Findings: Lesson from Stable vs Unstable Plaques

Stent strut coverage of titanium-nitride-oxide coated stent compared to paclitaxel-eluting stent in acute myocardial infarction: TITAX-OCT study

The MAIN-COMPARE Study

Complex PCI. Your partner in complex PCI: In-stent restenosis (ISR)

Bioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals

Bifurcation stenting with BVS

Unprotected LM intervention

Sirolimus-Eluting Stents for Treatment of In-Stent Restenosis

Vessel healings after stenting with different polymers in STEMI patients

European Heart Journal - Cardiovascular Imaging Advance Access published January 4, 2013

Case Report Coronary Artery Perforation and Regrowth of a Side Branch Occluded by a Polytetrafluoroethylene-Covered Stent Implantation

Insights in Thrombosis and In-Stent Restenosis

OCT Analysis in Patients With Very Late Stent Thrombosis

2yrs 2-6yrs >6yrs BMS 0% 22% 42% DES 29% 41% Nakazawa et al. J Am Coll Cardiol 2011;57:

Primary and mid-term outcome of sirolimus-eluting stent implantation with angiographic guidance alone

Stent thrombosis: How to manage it Dr Philip MacCarthy BSc PhD FRCP Consultant Cardiologist King s College Hospital, London, UK.

LM stenting - Cypher

Rationale and algorithm for below-the-knee acute gain optimization

Optical Coherence Tomography

BIOFREEDOM: Polymer free Biolimus A9 eluting

Clinical Investigations

Review Article Optical Coherence Tomography Imaging in Acute Coronary Syndromes

The wound healing response after implantation of a drug eluting stent is impaired persistently in the long term

Muzina Akhtar, Wei Liu. History of ISR visualization. Introduction

REVIEWS. Causes, assessment, and treatment of stent thrombosis intravascular imaging insights. Daniel S. Ong and Ik-Kyung Jang

Key Words Angioplasty Coronary artery disease Revascularization Stent drug eluting stent

Angiographic long-term results after implantation of the paclitaxel-eluting coronary stent coroflex please : Data under real-world conditions

Results of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents

A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience

PCI with Polymer-free Stent

Inspiron Stent. Clinical Research Program. Pedro A. Lemos MD PhD. Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil

Challenging of contrast agent-free endovascular treatment using 3D imaging

Optical coherence tomography patterns of in-stent restenosis: Comparison between bare-metal stent and drug-eluting stent

Bifurcation Stenting: IVUS and OCT Information

Left main coronary artery (LMCA): The proximal segment

Perioperative Management After Coronary Stenting: Risk Assessment Before Surgery. Christian Seiler No conflict of interest to declare.

Review Article Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement

Declaration of conflict of interest. Nothing to disclose

Journal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.

SMJ Singapore Medical Journal

The BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino

Ruofei Jia, Zening Jin, Hong Li, Jing Han. Introduction

Drug eluting stents From revolution to evolution. Current limitations

Intravascular Ultrasound in the Drug-Eluting Stent Era

Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan

Shedding light on stent thrombosis

Ενδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον. Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ

IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation

Index. B Bare metal stents (BMS) vs. DES, 172 OCT findings, 170, 172

The Role of Optical Coherence Tomography in Coronary Intervention

Intervention: How and to which extent is technology helping us?

PROMUS Element Experience In AMC

Results of TROFI II Study. Patrick W. Serruys, MD, PhD. Imperial college, London, UK On behalf of the PI s and the TROFI II investigators

A Randomized Optical Coherence Tomography Study of Coronary Stent Strut Coverage and Luminal Protrusion With Rapamycin-Eluting Stents

Interventional Cardiology

Imaging Atheroma The quest for the Vulnerable Plaque

The titanium nitride oxide stent an alternative to DES. Adam de Belder MD FRCP Sussex Cardiac Centre BSUH on behalf of Hexacath

Transcription:

Analysis of neointimal coverage after silolimus-eluting stent implantation using optical coherence tomography. Division of Cardiology, Department of Internal Medicine, Fasculty of Medicine, Kinki University, 377-2 Ohnohigashi Osakasayama Osaka, Japan Shinichiro Ikuta, Yoshitaka Iwanaga, Yoshihumi Nakauchi, Kenji Yamaji, Naoya Kobayashi, Hiroshi Yabushita, Takahiro Hayashi, Shunichi Miyazaki.

Background Drug Eluting Stent (DES) has been established to be effective in reducing restenosis after percutaneous coronary intervention (PCI). This benefit was due to its inhibitory effect on neointimal hyperplasia. However, this action of DES might induce a failure to complete neointimal coverage over the stent struts resulting in the crucial problem of the very late stent thrombosis.

Background (2) It is difficult to measure very thin neointimal thickness after stenting using intravascular ultrasound (IVUS), because its image resolution is approximately 100~200μm. On the other hand, optical coherence tomography (OCT) has potential advantage to evaluate neointimal thickness and the completeness of coverage because of the higher resolution (10μm) than IVUS.

Purpose Using OCT, we quantitatively measured the neointimal coverage at chronic stage after implantation of silolimuseluting stent (SES) and examined the difference of that after bare metal stent (BMS).

Patients Between April 2006 and February 2008, we enrolled 41 stents in 35 consecutive patients who underwent OCT examination with good quality of the image. SES; 33 stents in 28 patients BMS; 8 stents in 7 patients

Methods OCT imaging Pullback speed 1.0mm/s Measurement on the each slices The circumferential length of neointima was measured on the cross sectional plane in every 2mm from the distal edge of the stent. In the case of poor image, measurable cross sectional plane within 2 mm a point from the next image was substituted.

Representative case for the measurement of neointimal thickess. The vessel lumen boundary surface. Thickness of neointima The center of the stent strut

Classification of the neointimal coverage on the strut THK; The neointimal thickness is Thick (> 100μm). THN; The neointimal thickness is Thin( 10μm, 100μm) NON; Impossible to measure( <10μm) MAL; Strut not apposing the vessel wall (Malapposition) THK THN NON MAL

Example of OCT image of the SES THN; The neointima at the strut was 60μm. NON; The neointima at the strut was less than 10μm. MAL; Malapposition THK; The neointima at the strut was 200μm.

Representative case for measurement of the neointimal thickness on the struts of BMS All struts in the image were THK.

Expression of the percentage of the neointimal coverage. 1)The percentage of THK, THN, NON and MAL was calculated in each category divided by the whole number of struts and expressed as %THK, %THN, %NON and %MAL. 2)The percentage of NON was calculated in each stent and expressed as %NON/S.

Results: Patient characteristics SES BMS Number of patients 28 7 Number of stents 33 8 Male/Female 27/1 6/1 Age(years) 66.6 ± 8.4 68.7 ± 6.4 Clinical diagnosis Stable AP, Silent ischemia 15 Unstable angina pectoris 2 (Hemodialysis patient ) 1 Acute myocardial infarction 5 Restenosis of BMS 5 Chronic total occlusion 5 Unstable angina pectoris 2 (Emergent procedure) (2) (7) Follow up period (days) 263.2 ± 93.0 190.5 ± 30.2

Comparison of the average neointimal thickness SES BMS Total stents 33 8 Measured slices 405 64 Measured struts 3463 371 Average neointimal thickness (μm) 77.5 ±99.7 522.1 ±241.0

Comparison of the neointimal coverage %MAL 3.3% SES %THN 2.2% BMS %NON 19.3% %THK 25.2% %THN 52.3% %THK 97.8% Measured struts 3463 in SES. Measured struts 371 in BMS

Number of stents in which %NON/S was more than 5% SES N=33 %NON/S>5% N=26 < 5% N=5 0% N=2 BMS N=8 %NON/S=0% N=8

Number of stents including with MAL SES N=33 Malapposition(+) N=22 Malapposition(-) N=11 BMS N=8 Malapposition(-) N=8

The neointimal thickness on the struts of SES in the proximal, body and distal site. μm P<0.001 P<0.03 N=total 33 stents 3463 struts 100 80 60 40 20 0 95.2 ±112.5 69.7 ±97.4 78.8 ±89.9 Proximal Body Mid Distal

The neointimal thickness on the struts of BMS in the proximal, body and distal site. μm 600 N=total 8 stents 371 struts 500 400 300 200 100 535.7 ±239.2 532.4 ±235.8 485.8 ±252.9 0 Proximal Body Mid Distal

The malapposition struts of SES in the proximal, body and distal site. % 7 6 5 4 3 2 1 0 P<0.001 P<0.05 6.1% 3.4% 1.9% Proximal Body Mid Distal N=total 33 stents 3463 struts

Summary 1)The neointimal thickness of SES is thinner than that of BMS and 52% of all struts of SES were classified as THN. 2) Number of the stents in which neointima was judged as NON were 31/33 (93.9%) in SES. However no struts showed NON in BMS. 3)The neointimal thickness of SES were different depending on the distal, body and proximal site.

Conclusion The neointimal coverage of SES was insufficent in 22.6% (NON+MAL) of the struts and the thickness of neointima was different depending on the proximal or distal site of SES.